Definium Therapeutics (DFTX) Retained Earnings (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Retained Earnings data on file, last reported at -$659.8 million in Q1 2026.

• On a quarterly basis, Retained Earnings fell 56.28% year-over-year to -$659.8 million in Q1 2026; TTM through Mar 2026 was -$659.8 million, a 56.28% decrease from a year earlier, with the FY2025 full-year figure at -$582.7 million, down 46.08% from the prior year.
• Retained Earnings for Q1 2026 stood at -$659.8 million, down from -$582.7 million in the prior quarter.
• Over the last five years, Retained Earnings for DFTX reached as high as $850000.0 in Q2 2022 and fell as low as -$659.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$268.3 million across 5 years, with a median of -$248.4 million in 2023.
• Across the five-year window, Retained Earnings surged 100.41% in 2023 and plunged 116391.25% in 2024, its largest moves.
• Year by year, Retained Earnings stood at -$194.5 million in 2022, then surged by 100.18% to $343000.0 in 2023, then plunged by 116391.25% to -$398.9 million in 2024, then tumbled by 46.08% to -$582.7 million in 2025, then dropped by 13.24% to -$659.8 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$659.8 million in Q1 2026, -$582.7 million in Q4 2025, and -$532.2 million in Q3 2025.